日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

皮下注射曲妥珠单抗/帕妥珠单抗与静脉注射曲妥珠单抗:辅助曲妥珠单抗/帕妥珠单抗治疗I期HER2+乳腺癌II期试验的时间和动作子研究(ADEPT试验)

Waks, Adrienne G; Chen, Emily L; Graham, Noah; Frey, Anna Mae; Almeida, Kenneth; Attaya, Victoria; Ryding, Cari; Abbass, Ibrahim; Fung, Anita; Sussell, Jesse; Cortazar, Patricia; Harvey, Caroline; Leth, Denise; Faggen, Meredith; Sinclair, Natalie; Walsh, Jeanna; Tung, Nadine; Sinclair, Sarah; Lo, Steve; Yardley, Denise; Valero, Vicente; Meisel, Jane; Ballinger, Tarah J; Adams, Sylvia; Carey, Lisa A; Rauch, Julia K; Abramson, Vandana G; Williams, Nicole O; Chen, Wendy Y; Leone, Jose P; Schumer, Susan T; Tayob, Nabihah; Tolaney, Sara M

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

在铂类耐药的高级别浆液性卵巢癌中,贝佐塞替联合吉西他滨与单用吉西他滨的疗效比较:一项多中心、开放标签、随机、II期试验

Konstantinopoulos, Panagiotis A; Cheng, Su-Chun; Wahner Hendrickson, Andrea E; Penson, Richard T; Schumer, Susan T; Doyle, L Austin; Lee, Elizabeth K; Kohn, Elise C; Duska, Linda R; Crispens, Marta A; Olawaiye, Alexander B; Winer, Ira S; Barroilhet, Lisa M; Fu, Siqing; McHale, Michael T; Schilder, Russell J; Färkkilä, Anniina; Chowdhury, Dipanjan; Curtis, Jennifer; Quinn, Roxanne S; Bowes, Brittany; D'Andrea, Alan D; Shapiro, Geoffrey I; Matulonis, Ursula A

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

BIM介导EGFR酪氨酸激酶抑制剂诱导的具有致癌EGFR突变的肺癌细胞凋亡

Costa Daniel B, Halmos Balázs, Kumar Amit, Schumer Susan T, Huberman Mark S, Boggon Titus J, Tenen Daniel G, Kobayashi Susumu